Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial

BMC Women's Health

Nel Roeleveld¹  Hella E. C. Muijsers²  Angela H. E. M. Maas²  Peter Tönnies³  Chantal van Bijsterveldt⁴  Ciska Buijs⁵  Olivier W. H. van der Heijden⁶  Karin de Boer⁷  Susanne Heiden⁸  Jens Pagels⁹ 

[1] Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center;Department of Cardiology, Radboud university medical center;Department of Obstetrics and Gynecology, Bethanien Hospital Moers;Department of Obstetrics and Gynecology, Canisius-Wilhelmina Hospital;Department of Obstetrics and Gynecology, Maasziekenhuis Pantein;Department of Obstetrics and Gynecology, Radboud university medical center;Department of Obstetrics and Gynecology, Rijnstate;Department of Obstetrics and Gynecology, St. Antonius Hospital Kleve;Department of Obstetrics and Gynecology, St. Josef Hospital Moers;

关键词: Cardiovascular disease;    eHealth;    Preeclampsia;    Hypertension;    Home blood pressure monitoring;    Cardiovascular risk factor;   

DOI  :  10.1186/s12905-020-00910-0

来源: DOAJ

【 摘 要 】

Abstract Background Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) or the Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome are associated with elevated cardiovascular disease (CVD) risks, but standardized prevention guidelines after such pregnancies are lacking. Hypertension is the first emerging risk factor after PE/HELLP pregnancies and is a major risk factor for CVD. Hypertension before the age of 55 years may lead to various manifestations of end-organ damage at relatively young age. Therefore, timely treatment of elevated blood pressure is mandatory, but many of these high-risk women have long-term undetected and untreated hypertension before adequate treatment is initiated. Aim The aim of our study is to assess whether home blood pressure monitoring (HBPM) in women with a previous PE/HELLP pregnancy is a valuable tool for the early detection of hypertension. Methods Women with a history of both early and late PE/HELLP syndrome aged 40–60 years are invited to participate. Patients with a history of CVD, known hypertension and/or use of antihypertensive medication are excluded. Women are randomized between HPBM or ‘usual care’. The primary outcome is feasibility and usability of HBPM after 1 year of follow-up. Secondary outcomes will be the effectiveness of HPBM to detect hypertension, the efficacy of BP treatment, quality of life, health-related symptoms, work ability, and life-style behaviour. The results of this study will provide better strategies for timely detection and prevention of hypertension in women after PE/HELLP. Trial registration ClinicalTrials.gov , NCT03228082 . Registered June 15, 2017.

【 授权许可】

Unknown